April 2nd 2025
Subcutaneous pembrolizumab demonstrated comparable efficacy vs intravenous administration in non–small cell lung cancer, with a significantly shorter injection time.
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Annual Hawaii Cancer Conference
January 24-25, 2026
Register Now!
42nd Annual CFS: Chemotherapy Foundation Symposium®: Innovative Cancer Therapy for Tomorrow
View More
Genetic Testing is Essential in NSCLC Prior to Induction Therapy
November 12th 2019Testing for driver mutations is essential before initiating therapy in patients with non–small cell lung cancer, because there is a risk that the type of upfront treatment chosen could add to the toxicity of, and spur resistance to, targeted therapy options, Suresh S. Ramalingam, MD, said at the 14th Annual New York Lung Cancers Symposium.
Read More
Osimertinib Established as Preferred EGFR TKI Treatment in EGFR-Mutated NSCLC
November 12th 2019In an interview with Targeted Oncology during the 14th Annual New York Lung Cancers Symposium, Zofia Piotrowska, MD, MHS, discussed the role of osimertinib in treating patients with EGFR-mutant NSCLC and how it compares with other therapeutic options in that space.
Read More
Study Depicts Complexity of MET Exon 14 Mutation Testing
November 11th 2019The identification of <em>MET </em>exon 14 skipping mutations in patients with non–small cell lung cancer presents a complex diagnostic challenge that requires both DNA and RNA analysis, according to results of a University of Michigan pathology study.
Read More
Nivolumab/Ipilimumab Combination Shows Benefit in First-Line Setting for NSCLC
November 11th 2019Although the use of PD-1 and CTLA-4 pathway blockade in non–small cell lung cancer has had mixed results in the past, the combination of nivolumab and ipilimumab has demonstrated positive benefit in overall survival and adverse event profile compared with chemotherapy. Research suggests that anti–CTLA-4 helps induce T-cell responses and anti–PD-1 aids to restore anti-tumor T cell function.
Read More
Adjuvant Immunotherapy Combination Shows Activity in AXL-Positive NSCLC
November 11th 2019The combination of bemcentinib, a first in class selective AXL inhibitor, and pembrolizumab is well-tolerated in patients with composite AXL-positive non–small cell lung cancer, according to updated data presented at Society for Immunotherapy of Cancer’s 34th Annual Meeting.
Read More
Neoadjuvant Immunotherapy Holds Promise for Patients With Resectable NSCLC
November 10th 2019According to Tina Cascone, MD, PhD, in a presentation during the 14th Annual New York Lung Cancers Symposium, neoadjuvant immunotherapy is under investigation for patients with non–small cell lung cancer and holds hope as a treatment for patients.
Read More
Expert Reviews Evolving Treatment Options for Nondriver and Molecularly Driven NSCLC
November 10th 2019In an interview with <em>Targeted Oncology</em> during the <em>14th Annual </em>New York Lung Cancers Symposium, Benjamin P. Levy, MD, discussed therapeutic strategies for patients with oncogenic-driven and nondriver NSCLC.
Read More
Expert Discusses Benefits of Preoperative Therapy for NSCLC
November 10th 2019Noeadjuvant therapy for lung cancer provides significant benefits compared with adjuvant therapy, according to Jamie E. Chaft, MD. In a presentation at the <em>14th Annual </em>New York Lung Cancers Symposium, Chaft explained why neoadjuvant therapy is beneficial even though adjuvant therapy is still the standard of care at a number of cancer centers.
Read More
Poor Survival Rates Spur Research in Immunotherapy Combinations, PARP Inhibitors in SCLC
November 2nd 2019Despite advances in small cell lung cancer, overall 5-year survival remains at 5% to 10%. At the time of presentation, approximately 30% of patients with SCLC have limited stage disease, which is confined to the mediastinum, the hemithorax, or the supraclavicular lymph nodes. The remaining patients, who have extensive-stage SCLC, have tumors beyond the supraclavicular areas.
Read More
Presenters Seek to Answer Practical Questions of Lung Cancer Management at 2020 Winter Lung Meeting
November 1st 2019With so many advances occurring in the field of lung cancer and guidelines changing on an almost monthly basis, keeping up with the latest best practices has become more challenging for many oncologists. The 17th Annual Winter Lung Cancer Conference™ taking place February 7-9, 2020, in Miami, Florida, seeks to inform oncologists and healthcare professionals about the most up-to-date research and management suggestions.
Read More
PFS Prolonged With Frontline Durvalumab Triplet in Metastatic NSCLC
October 29th 2019Durvalumab in combination with tremelimumab and chemotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival in previously untreated patients with stage IV non–small cell lung cancer, according to findings from the final PFS analysis of the phase III POSEIDON trial.
Read More
Updated FLAURA Data Support FDA Approval of Osimertinib in EGFR+ NSCLC
October 24th 2019In an interview with <em>Targeted Oncology</em>, Suresh S. Ramalingam, MD, deputy director of Winship Cancer Institute of Emory University, discussed the updated OS results from the FLAURA trial and evaluated the role of osimertinib in patients with <em>EGFR-</em>mutant NSCLC. He also highlighted some next steps with research for this patient population, such as the potential combination of osimertinib with other agents.
Read More
FDA Approves New Aprepitant Dosing Regimen for CINV After MEC
October 23rd 2019The FDA has approved a supplemental New Drug Application for a single dose of aprepitant injectable emulsion for intravenous use in patients receiving moderately emetogenic chemotherapy. The approval expands the dose for aprepitant to include a 130 mg single-dose regimen for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.<br />
Read More
Nivolumab/Ipilimumab Plus Chemotherapy Demonstrates Frontline OS Benefit in NSCLC
October 22nd 2019Nivolumab in combination with low-dose ipilimumab and concomitant chemotherapy demonstrated a benefit in overall survival compared with chemotherapy alone in patients with previously untreated advanced non–small cell lung cancer, according to interim results from the CheckMate -9LA trial.
Read More
Osimertinib/Cetuximab Inhibits Tumor Growth in EGFR-Mutant NSCLC
October 18th 2019The lack of approved therapies to target EGFR exon 20 insertion mutations, the third most common form of EGFR mutations, led to the study of osimertinib in combination with cetuximab in patients with advanced EGFR-mutant non–small cell lung cancer.<br />
Read More
Langer Highlights the Potential Benefits of Postchemoradiation Immunotherapy in NSCLC
October 17th 2019In a Targeted Oncology case-based peer perspectives live discussion with a group of physicians, Corey J. Langer, MD, reviewed the potential for treatment with immunotherapy following chemoradiotherapy for patients with stage III non–small cell lung cancer. Langer discussed these options based off of a case scenario of a patient with stage IIIA lung adenocarcinoma.
Read More
Ramucirumab Plus Erlotinib Shows PFS Benefit in Frontline EGFR+ NSCLC
October 16th 2019Patients with treatment-naïve EGFR-mutant non–small cell lung cancer experienced a statistically significant and clinically meaningful improvement in progression-free survival with the combination of ramucirumab and erlotinib compared with erlotinib alone, according to the results of the phase III RELAY trial which was recently published in The Lancet Oncology.
Read More
Durvalumab Combination Improves Outcomes in Patients With ES-SCLC
October 16th 2019In an interview with Targeted Oncology, Luis Paz-Ares, MD, PhD, discussed the findings for the CASPIAN trial that were presented at the 2019 ESMO Congress. He also addressed what next steps are necessary to further develop the durvalumab combination in this setting.
Read More
Identification of Certain Tumor Characteristics Enhances Immunotherapy Response in NSCLC
October 15th 2019Advances in the development of targeted therapies and the identification of emerging biomarkers of response to treatment have led to an improved ability to predict and enhance responses to immunotherapeutic agents in non–small cell lung cancer.
Read More
Patients With Rare Gene Fusion NRG1 Respond to Afatinib in NSCLC
October 14th 2019Four patients with lung adenocarcinoma with NRG1 fusions demonstrated some degree of response or tumor stabilization when given afatinib, according to a poster presentation at the 2019 World Conference on Lung Cancer meeting. The findings suggest that the irreversible pan-ERBB inhibitor is a potential treatment in this rare mutation of lung adenocarcinoma.
Read More
Patients With Small Cell Lung Cancer Experience Tumor Response With Liposomal Irinotecan
October 12th 2019Findings from part 1 of the phase II/III RESILIENT trial of irinotecan hydrochloride liposome injection in second-line treatment of small cell lung cancer showed that for close to 50% of patients, disease control was maintained at 12 weeks. These data were presented at the 2019 World Conference on Lung Cancer.
Read More
Case Series Reveals Activity of Afatinib in NRG1+ Solid Tumors
October 11th 2019In a presentation at the 2019 ESMO Congress on a case series of 7 pretreated patients with <em>NRG1</em>-positive tumors, Stephen Liu, MD, and colleagues discussed the efficacy of afatinib and explained that afatinib may be a potential treatment option for <em>NRG1</em>-positive tumors across multiple cancer types.
Read More
Expert Reports Mixed Results in Interim Analysis for Multiarm NSCLC Trial
October 11th 2019Findings from an interim analysis of the National Lung Matrix Trial, a large, multiarm trial involving patients with non–small cell lung cancer, demonstrated both promising activity and shortcomings in predefined goals in a presentation at the 2019 World Conference on Lung Cancer.
Read More
Experts Calls for More Research on Predictive Biomarkers for Immunotherapy Treatment in NSCLC
October 10th 2019In an interview with <em>Targeted Oncology</em>, Negrao, assistant professor, The University of Texas MD Anderson Cancer Center, reviewed data from the study of response to ICB therapy in patients with oncogene-driven non–small cell lung cancer.
Read More
New Insights From Genomic Classification Affecting Choice of Targeted Agents or Immunotherapy
October 10th 2019At the recent <em>20th Annual </em>International Lung Cancer Congress® in Huntington Beach, California, a number of very prominent contributors to the lung cancer translational and clinical field provided updates regarding novel strategies to address unmet needs.
Read More
More Immunotherapy Regimens in NSCLC Highlight the Importance of Biomarkers
October 8th 2019The wealth of new data available for the treatment of patients with non–small cell lung cancer has led to numerous effective immunotherapy combinations in similar patient subsets, explained Karen L. Reckamp, MD, MS. Clinical trials going forward seem to primarily focus on the combination of immunotherapeutic and targeted agents, which may result in even more options for this tumor type.
Read More
Blood-Based Biomarkers Useful in NSCLC Management
October 8th 2019Multiple presentations at the 2019 ESMO Congress add to the evidence that blood-based biomarkers have predictive utility in advanced non-small cell lung cancer. Blood-based next-generation sequencing has also shown clinical utility in aiding treatment decisions for physicians treating this disease.
Read More